MedPath

Dexmedetomidine-Propofol Versus Ketamine-Propofol for Sedation of CT Guided Bone Biopsy

Phase 4
Completed
Conditions
Sedation
Interventions
Drug: Dexmedetomidine-propofol
Drug: Ketamine-Propofol
Registration Number
NCT05752903
Lead Sponsor
National Cancer Institute, Egypt
Brief Summary

This study aims to compare the effectiveness and safety of a dexmedetomidine-propofol combination and a ketamine-Propofol combination for sedation of CT guided bone biopsy.

Detailed Description

Assessment of boney lesions is an common activity in the care of cancer patients. CT guided Percutaneous needle biopsies have a low complication rate. usually, this procedure is done under sedation.

Propofol is a non-barbiturate hypnotic and sedative. It facilitates gamma-aminobutyric acid mediated inhibitory neurotransmission. It's known to have anti-emetic, antipruritic, anticonvulsant and amnestic effects. Despite being effective and potent, Propofol's main disadvantages is its dose-dependent hypotension and respiratory depression .Ketamine is a phencyclidine derivative which acts as a N-methyl-D-aspartate (NMDA) receptor antagonist. It is a dissociative anesthetic and provides some analgesia. It maintains airway reflexes and spontaneous respiration. Combining Propofol and ketamine preserves the sedative and analgesic efficacy while reducing their adverse effects. Dexmedetomidine is a highly selective α2-agonist. It is eight times more specific compared with clonidine. It has a perioperative anxiolytic, sedative properties as well as some analgesic properties .Dexmedetomidine is usually used for mild to moderate sedation and Propofol could be added to deepen the level of sedation

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Stated willingness to comply with all study procedures and availability for the duration of the study .
  • Age between 18 to 60 years old
  • American Society of Anesthesiologists (ASA) physical I-III
  • Scheduled for CT guided bone biopsy with sedation.
Exclusion Criteria
  • Severe heart, lung, and liver disease
  • kidney failure
  • Bleeding diathesis Allergy to drugs to be used

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Dexmedetomidine-propofolDexmedetomidine-propofolDexmedetomidine-propofol bolus will be administered then Dexmedetomidine-propofol infusion continued during the procedure
ketamine-propofolKetamine-Propofolketamine-propofol bolus will be administered then Dexmedetomidine-propofol infusion continued during the procedure
Primary Outcome Measures
NameTimeMethod
Heart ratebefore administration (baseline), every 10 minutes during the procedure, every 15 minutes for one hour postoperatively

change in heart rate

Secondary Outcome Measures
NameTimeMethod
Mean arterial blood pressurebefore administration (baseline), every 10 minutes during the procedure, every 15 minutes for one hour postoperatively

change in the mean arterial blood pressure

Visual analogue scale (VAS) score for painevery 15 minutes for one hour postoperatively

assessment of postoperative pain using the visual analogue scale score. the scale is a straight horizontal line (100 mm). The ends are defined as the extreme limits of pain orientated from the left (no pain) to the right (worst pain).The patient marks on the line the point that they feel represents their perception of their current state.

The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks.higher VAS score means worse pain

recovery timeimmediately postoperative

recovery time

Trial Locations

Locations (1)

National cancer institute

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath